uploads///GILD

What Does Gilead Sciences’ Bottom-Line Trend Indicate?

By

Dec. 4 2020, Updated 10:52 a.m. ET

Bottom line

Gilead Sciences’ (GILD) interest expense decreased from $291.0 million in the third quarter of 2017 to $264.0 million in the third quarter. The company’s income tax provision also decreased from $959.0 million in the third quarter of 2017 to $565.0 million in the third quarter.

The continued decrease in the top line and higher operating expenses caused Gilead Sciences’ net income to fall from $2.72 billion in the third quarter of 2017 to $2.1 billion in the third quarter, which translated into a net EPS of $1.60 in the third quarter. Gilead Sciences’ net EPS was $2.06 in the third quarter of 2017.

Article continues below advertisement

Geographic performance

Gilead Sciences geographic performance includes the US, Europe, and Other International segments. The company’s US revenues decreased from $4.54 billion in the third quarter of 2017 to $4.13 billion in the third quarter.

The company’s revenues from Europe decreased from $1.2 billion in the third quarter of 2017 to $873.0 million in the third quarter. Gilead Sciences’ revenues from the Other International segment decreased from $663.0 million in the third quarter of 2017 to $451.0 million in the third quarter.

Gilead Sciences’ cash per share stands at $19.97. In comparison, Bristol-Myers Squibb (BMY), Merck (MRK), and Pfizer’s (PFE) cash per share stand at $4.19, $2.83, and $2.25, respectively.

Next, we’ll discuss Gilead Sciences’ HIV sales trend.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.